Last reviewed · How we verify
NCT04923789
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
trial in Relapsed Non Hodgkin Lymphoma in 60 participants. Status unknown.
1 March 2022
Quick facts
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 1 September 2020 |
| Primary completion | 1 March 2022 |
| Estimated completion | 1 March 2023 |
| Sites | 1 location across China |
Conditions studied
- Relapsed Non Hodgkin Lymphoma — all drugs for Relapsed Non Hodgkin Lymphoma →
- Refractory Non-Hodgkin Lymphoma — all drugs for Refractory Non-Hodgkin Lymphoma →
Sponsor
The First Affiliated Hospital of Soochow University
Who can join
Adults 18 to 65, any sex, with Relapsed Non Hodgkin Lymphoma or Refractory Non-Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single center, prospective cohort study to to evaluate the efficacy and safety of autologous hematopoietic stem cell transplantation(ASCT) bridging chimeric antigen receptor T (CART) cell therapy in the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
Xiao X, Wang Y, Zou Z, Yang Y, et al · · 2022 · cited 20× · PMID 36091028 · DOI 10.3389/fimmu.2022.954235 -
Autologous stem cell transplantation meets CAR-T therapy: A synergistic strategy for B-cell lymphoma.
Zhao X, Wu J, Zhu X, Xiao Y. · · 2025 · PMID 41137502 · DOI 10.1177/09636897251379571
Verify or expand the search:
- PubMed search for NCT04923789
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Relapsed Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT05260957 — CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma · Phase 2 · recruiting
- NCT03774654 — CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) · Phase 1 · active not recruiting
Other The First Affiliated Hospital of Soochow University trials
Trials by the same sponsor.
- NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
- NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
- NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04923789 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
- Last refreshed: 11 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04923789.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing